Search Results - "SHEPPARD, Neil"

Nanomaterials for T-cell cancer immunotherapy by Gong, Ningqiang, Sheppard, Neil C., Billingsley, Margaret M., June, Carl H., Mitchell, Michael J.

“…T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with three approved products for B-cell malignancies and a large pipeline…”
Get full text

Genetic engineering of T cells for immunotherapy by Ellis, Gavin I., Sheppard, Neil C., Riley, James L.

“…Genetically engineered T cell immunotherapies have provided remarkable clinical success to treat B cell acute lymphoblastic leukaemia by harnessing a patient’s…”
Get full text

Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells by Mai, David, Johnson, Omar, Reff, Jordan, Fan, Ting-Jia, Scholler, John, Sheppard, Neil C, June, Carl H

“…A fundamental limitation of T cell therapies in solid tumors is loss of inflammatory effector functions, such as cytokine production and proliferation. Here,…”
Get full text

In vivo gene immunotherapy for cancer by Mai, David, June, Carl H, Sheppard, Neil C

“…Cancer is becoming increasingly understood not only as a disease of pathological cells but also as one of immune hypofunction. The heterogenous and…”
Get more information

Swiss army knife T cell: one T cell many tumor targets by Berjis, Abdulla, Muthumani, Deeksha, Sheppard, Neil C., June, Carl H.

Get full text

Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells by Billingsley, Margaret M, Hamilton, Alex G, Mai, David, Patel, Savan K, Swingle, Kelsey L, Sheppard, Neil C, June, Carl H, Mitchell, Michael J

“…Viral engineered chimeric antigen receptor (CAR) T cell therapies are potent, targeted cancer immunotherapies, but their permanent CAR expression can lead to…”
Get full text

ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cells by Mai, David, Boyce, Tifara, Mehta, Aakash, Reff, Jordan, Scholler, John, Sheppard, Neil C., June, Carl H.

“…Loss of inflammatory effector function, such as cytokine production and proliferation, is a fundamental driver of failure in T cell therapies against solid…”
Get full text

Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation by Berjis, Abdulla, Muthumani, Deeksha, Aguilar, Oscar A., Pomp, Oz, Johnson, Omar, Finck, Amanda V., Engel, Nils W., Chen, Linhui, Plachta, Nicolas, Scholler, John, Lanier, Lewis L., June, Carl H., Sheppard, Neil C.

“…Human natural killer (NK) cell-based therapies are under assessment for treating various cancers, but cryopreservation reduces both the recovery and function…”
Get full text

Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors by Zhong, Wenqun, Xiao, Zebin, Qin, Zhiyuan, Yang, Jingbo, Wen, Yi, Yu, Ziyan, Li, Yumei, Sheppard, Neil C, Fuchs, Serge Y, Xu, Xiaowei, Herlyn, Meenhard, June, Carl H, Puré, Ellen, Guo, Wei

“…Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited…”
Get full text

Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy by Metzloff, Ann E., Padilla, Marshall S., Gong, Ningqiang, Billingsley, Margaret M., Han, Xuexiang, Merolle, Maria, Mai, David, Figueroa‐Espada, Christian G., Thatte, Ajay S., Haley, Rebecca M., Mukalel, Alvin J., Hamilton, Alex G., Alameh, Mohamad‐Gabriel, Weissman, Drew, Sheppard, Neil C., June, Carl H., Mitchell, Michael J.

“…Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable clinical success in the treatment of hematological malignancies. However, producing…”
Get full text

Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens by Sheppard, Neil C, Brinckmann, Sarah A, Gartlan, Kate H, Puthia, Manoj, Svanborg, Catharina, Krashias, George, Eisenbarth, Stephanie C, Flavell, Richard A, Sattentau, Quentin J, Wegmann, Frank

“…Polyethyleneimine (PEI) is an organic polycation used extensively as a gene and DNA vaccine delivery reagent. Although the DNA targeting activity of PEI is…”
Get full text

Responsive biomaterials: optimizing control of cancer immunotherapy by Xue, Lulu, Thatte, Ajay S., Mai, David, Haley, Rebecca M., Gong, Ningqiang, Han, Xuexiang, Wang, Karin, Sheppard, Neil C., June, Carl H., Mitchell, Michael J.

“…Immunotherapy has emerged as an eminent and effective modality in the treatment of cancer. However, current cancer immunotherapies lack spatial and temporal…”
Get full text

Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells by Haas, Andrew R., Golden, Ryan J., Litzky, Leslie A., Engels, Boris, Zhao, Linlin, Xu, Fangmin, Taraszka, John A., Ramones, Melissa, Granda, Brian, Chang, Wan-Jung, Jadlowsky, Julie, Shea, Kim-Marie, Runkle, Adam, Chew, Anne, Dowd, Emily, Gonzalez, Vanessa, Chen, Fang, Liu, Xiaojun, Fang, Chongyun, Jiang, Shuguang, Davis, Megan M., Sheppard, Neil C., Zhao, Yangbing, Fraietta, Joseph A., Lacey, Simon F., Plesa, Gabriela, Melenhorst, J. Joseph, Mansfield, Keith, Brogdon, Jennifer L., Young, Regina M., Albelda, Steven M., June, Carl H., Tanyi, Janos L.

“…Multiple clinical studies have treated mesothelin (MSLN)-positive solid tumors by administering MSLN-directed chimeric antigen receptor (CAR) T cells. Although…”
Get full text

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy by Tang, Yan, Liu, Wei, Kadu, Siddhant, Johnson, Omar, Hasanali, Zainul S., Kelly, Andre, Shestov, Alexander, Greenblatt, Eli, Holmes, Matthew, Wang, Li-Ping, Shih, Natalie, O’Connor, Roddy S., Garfall, Alfred L., Allman, David, Vogl, Dan T., Cohen, Adam, June, Carl H., Sheppard, Neil C.

“…•The levels of CD200 expressed by aberrant plasma cells in MM are sufficient to inhibit the activity of CAR T cells.•Compared with CD200R-knockout and…”
Get full text

Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens by Wegmann, Frank, Gartlan, Kate H, Harandi, Ali M, Brinckmann, Sarah A, Coccia, Margherita, Hillson, William R, Kok, Wai Ling, Cole, Suzanne, Ho, Ling-Pei, Lambe, Teresa, Puthia, Manoj, Svanborg, Catharina, Scherer, Erin M, Krashias, George, Williams, Adam, Blattman, Joseph N, Greenberg, Philip D, Flavell, Richard A, Moghaddam, Amin E, Sheppard, Neil C, Sattentau, Quentin J

“…No mucosal adjuvant formulation is approved for clinical use, even though boosting immunity at sites of pathogen entry should increase the efficacy of…”
Get full text

Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy (Adv. Mater. 26/2024) by Metzloff, Ann E., Padilla, Marshall S., Gong, Ningqiang, Billingsley, Margaret M., Han, Xuexiang, Merolle, Maria, Mai, David, Figueroa‐Espada, Christian G., Thatte, Ajay S., Haley, Rebecca M., Mukalel, Alvin J., Hamilton, Alex G., Alameh, Mohamad‐Gabriel, Weissman, Drew, Sheppard, Neil C., June, Carl H., Mitchell, Michael J.

“…Cancer Immunotherapy In article number 2313226, Ann E. Metzloff, Michael J. Mitchell, and co‐workers develop activating lipid nanoparticles (aLNPs) for cancer…”
Get full text

Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function by Zhang, Caimei, Kadu, Siddhant, Xiao, Yansen, Johnson, Omar, Kelly, Andre, O'Connor, Roddy S, Lai, Meizan, Kong, Hong, Srivatsa, Sriram, Tai, Victoria, Greenblatt, Eli, Holmes, Matthew, Riley, James L, June, Carl H, Sheppard, Neil C

“…Natural killer (NK) cells are frequently expanded for the clinic using irradiated, engineered K562 feeder cells expressing a core transgene set of…”
Get more information

Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering by Hamilton, Alex G., Swingle, Kelsey L., Joseph, Ryann A., Mai, David, Gong, Ningqiang, Billingsley, Margaret M., Alameh, Mohamad‐Gabriel, Weissman, Drew, Sheppard, Neil C., June, Carl H., Mitchell, Michael J.

“…The programmed cell death protein 1 (PD‐1) signaling pathway is a major source of dampened T cell activity in the tumor microenvironment. While clinical…”
Get full text

Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager by Gong, Ningqiang, Han, Xuexiang, Xue, Lulu, Billingsley, Margaret M., Huang, Xisha, El-Mayta, Rakan, Qin, Jingya, Sheppard, Neil C., June, Carl H., Mitchell, Michael J.

“…The broader clinical use of bispecific T cell engagers for inducing anti-tumour toxicity is hindered by their on-target off-tumour toxicity and the associated…”
Get full text

Author Correction: Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager by Gong, Ningqiang, Han, Xuexiang, Xue, Lulu, Billingsley, Margaret M., Huang, Xisha, El-Mayta, Rakan, Qin, Jingya, Sheppard, Neil C., June, Carl H., Mitchell, Michael J.

Get full text